Working… Menu

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04126070
Recruitment Status : Recruiting
First Posted : October 14, 2019
Last Update Posted : March 4, 2020
Bristol-Myers Squibb
Information provided by (Responsible Party):
Xiao X. Wei, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : June 30, 2025